Search
Bermekimab
go.drugbank.com/drugs/DB14947InvestigationalBermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
Edasalonexent
go.drugbank.com/drugs/DB15010InvestigationalEdasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).
Vunakizumab
go.drugbank.com/drugs/DB15154InvestigationalVunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis).
Ofranergene obadenovec
go.drugbank.com/drugs/DB15175InvestigationalOfranergene obadenovec is under investigation in clinical trial NCT01229865 (Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer).
MK-0533
go.drugbank.com/drugs/DB15242InvestigationalMK-0533 is under investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)).
ATB-346
go.drugbank.com/drugs/DB15377InvestigationalATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).
SP-420
go.drugbank.com/drugs/DB16069InvestigationalSP-420 is under investigation in clinical trial NCT03801889 (SP-420 in Subjects With Transfusion-dependent Beta-thalassemia or Other Rare Anemias).
Categories: Heterocyclic Compounds, 1-RingISIS 2503
go.drugbank.com/drugs/DB16181InvestigationalISIS 2503 is under investigation in clinical trial NCT00004193 (ISIS 2503 in Treating Patients With Metastatic And/or Locally Recurrent Colorectal Cancer).
Synonyms: H-ras antisense oligodeoxynucleotide isis 2503Felzartamab
go.drugbank.com/drugs/DB16375InvestigationalFelzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).
Autogene cevumeran
go.drugbank.com/drugs/DB17497InvestigationalAutogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.